Expression of Ki-67, galectin-3, fragile histidine triad, and parafibromin in malignant and benign parathyroid tumors

Chinese Medical Journal

Volumn 125, Issue 16, 2012, Pages 2895-2901

  Wang, Ou ^a   Wang, Chun yan ^b   Shi, Jie ^a   Nie, Min ^a   Xia, Wei bo ^a   Li, Mei ^a   Jiang, Yan ^a   Guan, Heng ^a   Meng, Xun wu ^a   Xing, Xiao ping ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b Aviation General Hospital   (China)

Author keywords

Fragile histidine triad gene; Galectin 3; Ki 67; Parafibromin; Parathyroid tumors

Indexed keywords

FRAGILE HISTIDINE TRIAD PROTEIN; GALECTIN 3; KI 67 ANTIGEN; PARAFIBROMIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BENIGN TUMOR; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MALIGNANT NEOPLASTIC DISEASE; PARATHYROID ADENOMA; PARATHYROID CARCINOMA; PARATHYROID HYPERPLASIA; PREDICTIVE VALUE; PRIMARY HYPERPARATHYROIDISM; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

ACID ANHYDRIDE HYDROLASES; GALECTIN 3; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; NEOPLASM PROTEINS; PARATHYROID NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 84865371836     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.16.018     Document Type: Article

References (30)

1. Bringhurst FR, DeMay MB, Kronenberg HM. Hormones and disorders of mineral metabolism. In: Larsen PR, Kronenberg HM, Melmed S, Polonsky KS, eds. Williams Textbook of Endocrinology. 10th ed. Philadelphia Pa: Saunders; 2003: 1303-1372
2. Bondeson L, Grimeluis L, DeLellis RA. Parathyroid carcinoma. In: DeLellis RA, Lloyd RV, Heitz PN, Eng C, eds. Pathology and genetics of tumours of endocrine organs (WHO classification). Lyon: IARC; 2004: 224-221.
3. DeLellis RA. Parathyroid carcinoma: An overview. Adv Anat Pathol 2005; 12: 53-61.
4. Wang O, Xing X, Meng X, Xia W, Li M, Zhu Y, et al. Comparison of clinical characteristics in primary hyperparathyroidism among different pathologic types. Chin J Pract Intern Med (Chin) 2006; 26: 1798-1801.
5. Rodgers SE, Perrier ND. Parathyroid carcinoma. Curr Opin Oncol 2006; 18: 16-21.
6. Iacobone M, Ruffolo C, Lumachi F, Favia G. Results of iterative surgery for persistent and recurrent parathyroid carcinoma. Langenbecks Arch Surg 2005; 390: 385-391.
7. Cetani F, Pardi E, Viacava P, Pollina GD, Fanelli G, Picone A, et al. A reappraisal of the Rb1 gene abnormalities in the diagnosis of parathyroid cancer. Clin Endocrinol (Oxf) 2004; 60: 99-101.
8. Hadar T, Shvero J, Yaniv E, Ram E, Shvili I, Koren R. Expression of p53, Ki-67 and Bcl-2 in parathyroid adenoma and residual normal tissue. Pathol Oncol Res 2005; 11: 45-41.
9. Buchwald PC, Akerström G, Westin G. Reduced p18INK4c, p21CIP1/WAF1 and p27KIP1 mRNA levels in tumours of primary and secondary hyperparathyroidism. Clin Endocrinol (Oxf) 2004; 60: 389-391.
10. Hemmer S, Wasenius VM, Haglund C, Zhu Y, Knuutila S, Franssila K, et al. Deletion of 11q23 and cyclin D1 overexpression are frequent aberrations in parathyroid adenomas. Am J Pathol 2001; 158: 1355-1361.
11. Cristobal E, Arribas B, Tardio J, Aicazar JA, Matinez-Montero JC, Carrion R, et al. Analysis of the Cycilin D1/p16/pRb pathway in parathyroid adenomas. Endocr Pathol 2000; 11: 259-261.
12. Fernandez-Ranvier GG, Khanafshar E, Tacha D, Wong M, Kebebew E, Duh QY, et al. Defining a molecular phenotype for benign and malignant parathyroid tumors. Cancer 2009; 115: 334-341.
13. Thomopoulou GE, Tseleni-Balafouta S, Lazaris AC. Immunohistochemical detection of cell cycle regulators, Fhit protein and apoptotic cells in parathyroid lesions. Eur J Endocrinol 2003; 148: 81-81.
14. Orlandi F, Saggiorato E, Pivano G, Puligheddu B, Termine A, Cappia S, et al. Galectin-3 is a presurgical marker of human thyroid carcinoma. Cancer Res 1998; 58: 3015-3021.
15. Perillo NL, Marcus ME, Baum LG. Galectins: versatile modulators of cell adhesion, cell proliferation, and cell death. J Mol Med 1998; 76: 402-411.
16. Bergero N, De Pompa R, Sacerdote C, Gasparri G, Volante M, Bussolati G, et al. Galectin-3 expression in parathyroid carcinoma: immunohistochemical study of 26 cases. Hum Pathol 2005; 36: 908-911.
17. Carpten JD, Robbins CM, Villablanca A, Forsberg L, Presciuttini S, Bailey-Wilson J. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet 2002; 32: 676-681.
18. Gill AJ, Clarkson A, Gimm O, Keil J, Dralle H, Howell VM, et al. Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias. Am J Surg Pathol 2006; 30: 1140-1141.
19. Yart A, Gstaiger M, Wirbelauer C, Pecnik M, Anastasiou D, Hess D, et al. The HRPT2 tumor suppressor gene product parafibromin associates with human PAF1 and RNA polymerase II. Mol Cell Biol 2005; 25: 5052-5061.
20. Rozenblatt-Rosen O, Hughes CM, Nannepaga SJ, Shanmugam KS, Copeland TD, Guszczynski T, et al. The parafibromin tumor suppressor protein is part of a human Paf1 complex. Mol Cell Biol 2005; 25: 612-621.
21. Zhang C, Kong D, Tan MH, Pappas DL Jr, Wang PF, Chen J, et al. Parafibromin inhibits cancer cell growth and causes G1 phase arrest. Biochem Biophys Res Commun 2006; 350: 17-21.
22. Bradley KJ, Bowl MR, Williams SE, Ahmad BN, Partridge CJ, Patmanidi AL, et al. Parafibromin is a nuclear protein with a functional monopartite nuclear localization signal. Oncogene 2007; 26: 1213-1221.
23. Mosimann C, Hausmann G, Basler K. Parafibromin/Hyrax activates Wnt/Wg target gene transcription by direct association with beta-catenin/Armadillo. Cell 2006; 125: 327-341.
24. Yang YJ, Han JW, Youn HD, Cho EJ. The tumor suppressor, parafibromin, mediates histone H3 K9 methylation for cyclin D1 repression. Nucleic Acids Res 2010; 38: 382-391.
25. Juhlin CC, Villablanca A, Sandelin K, Haglund F, Nordenström J, Forsberg L, et al. Parafibromin immunoreactivity: its use as an additional diagnostic marker for parathyroid tumor classification. Endocr Relat Cancer 2007; 14: 501-511.
26. Shattuck TM, Valimaki S, Obara T, Gaz RD, Clark OH, Shoback D, et al. Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med 2003; 349: 1722-1721.
27. Cetani F, Ambrogini E, Viacava P, Pardi E, Fanelli G, Naccarato AG, et al. Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma? Eur J Endocrinol 2007; 156: 547-551.
28. Saggiorato E, Bergero N, Volante M, Bacillo E, Rosas R, Gasparri G, et al. Galectin-3 and Ki-67 expression in multiglandular parathyroid lesions. Am J Clin Pathol 2006; 126: 59-61.
29. Kameyama K, Takami H, Umemura S, Osamura YR, Wada N, Sugino K, et al. PCNA and Ki-67 as prognostic markers in human parathyroid carcinomas. Ann Surg Oncol 2000; 7: 301-301.
30. Wang X, Sun B, Zhou F, Hu J, Yu X, Peng T. Vitamin D receptor and PCNA expression in severe parathyroid hyperplasia of uremic patients. Chin Med J 2001; 114: 410-414.